I'm saying we should be able to look at those most critically in need—those patients, like my group of patients, who will be dead before we decide to fund it. I guarantee you, we will decide to fund this drug in this country. Most drugs that are granted priority approval move on to be reimbursed, or they move on to put a collaborative deal in place between governments and pharmaceutical companies.
What we shouldn't be doing is taking our time to make that happen, because we're losing a lot of people. If we have a drug that is granted priority review, it's granted priority review for a reason. We should be able to make sure there are mechanisms in place to reimburse that.